266 related articles for article (PubMed ID: 30887749)
21. Tumor immunity is related to
Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
[TBL] [Abstract][Full Text] [Related]
22. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
23. Is (18)F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? A meta-analysis.
Treglia G; Sadeghi R; Giovanella L; Cafarotti S; Filosso P; Lococo F
Lung Cancer; 2014 Oct; 86(1):5-13. PubMed ID: 25175317
[TBL] [Abstract][Full Text] [Related]
24. Incidental mediastinal masses detected at low-dose CT screening: prevalence and radiological characteristics.
Miyazawa R; Matsusako M; Nozaki T; Kobayashi D; Kojima F; Bando T; Tateishi U
Jpn J Radiol; 2020 Dec; 38(12):1150-1157. PubMed ID: 32638279
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Value of Dual-time-point F-18 FDG PET/CT and Chest CT for the Prediction of Thymic Epithelial Neoplasms.
Shinya T; Tanaka T; Soh J; Matsushita T; Sato S; Toyooka S; Yoshino T; Miyoshi S; Kanazawa S
Acta Med Okayama; 2017 Apr; 71(2):105-112. PubMed ID: 28420891
[TBL] [Abstract][Full Text] [Related]
26. [18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning.
Travaini LL; Petralia G; Trifirò G; Ravasi L; Galetta D; Carbone G; Falcini F; Spaggiari L; Bellomi M; Paganelli G
Lung Cancer; 2008 Sep; 61(3):362-8. PubMed ID: 18358558
[TBL] [Abstract][Full Text] [Related]
27. A radiomics model to predict the invasiveness of thymic epithelial tumors based on contrast‑enhanced computed tomography.
Chen X; Feng B; Li C; Duan X; Chen Y; Li Z; Liu Z; Zhang C; Long W
Oncol Rep; 2020 Apr; 43(4):1256-1266. PubMed ID: 32323834
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Pathologic Grade and Prognosis in Mucoepidermoid Carcinoma of the Lung Using ¹⁸F-FDG PET/CT.
Park B; Kim HK; Choi YS; Kim J; Zo JI; Choi JY; Shim YM
Korean J Radiol; 2015; 16(4):929-35. PubMed ID: 26175595
[TBL] [Abstract][Full Text] [Related]
29. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
30. Improved detection of metastatic lymph nodes in oesophageal squamous cell carcinoma by combined interpretation of fluorine-18-fluorodeoxyglucose positron-emission tomography/computed tomography.
Lee JY; Kim YH; Park YJ; Park SB; Chung HW; Zo JI; Shim YM; Lee KS; Choi JY
Cancer Imaging; 2019 Jun; 19(1):40. PubMed ID: 31227017
[TBL] [Abstract][Full Text] [Related]
31. Is a positron emission tomography-computed tomography scan useful in the staging of thymic epithelial neoplasms?
Viti A; Terzi A; Bianchi A; Bertolaccini L
Interact Cardiovasc Thorac Surg; 2014 Jul; 19(1):129-34. PubMed ID: 24648467
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms.
Terzi A; Bertolaccini L; Rizzardi G; Luzzi L; Bianchi A; Campione A; Comino A; Biggi A
Lung Cancer; 2011 Nov; 74(2):239-43. PubMed ID: 21439670
[TBL] [Abstract][Full Text] [Related]
33. ¹⁸F-fluorodeoxyglucose positron emission tomography for evaluation of thymic epithelial tumors: utility for World Health Organization classification and predicting recurrence-free survival.
Seki N; Sakamoto S; Karube Y; Oyaizu T; Ishihama H; Chida M
Ann Nucl Med; 2014 Apr; 28(3):257-62. PubMed ID: 24430867
[TBL] [Abstract][Full Text] [Related]
34. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
[TBL] [Abstract][Full Text] [Related]
35. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K
Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
[TBL] [Abstract][Full Text] [Related]
36. Diffusion Weighted Imaging Can Distinguish Benign from Malignant Mediastinal Tumors and Mass Lesions: Comparison with Positron Emission Tomography.
Usuda K; Maeda S; Motono N; Ueno M; Tanaka M; Machida Y; Matoba M; Watanabe N; Tonami H; Ueda Y; Sagawa M
Asian Pac J Cancer Prev; 2015; 16(15):6469-75. PubMed ID: 26434861
[TBL] [Abstract][Full Text] [Related]
37. Characterization of thymic masses using (18)F-FDG PET-CT.
Kumar A; Regmi SK; Dutta R; Kumar R; Gupta SD; Das P; Halanaik D; Jindal T
Ann Nucl Med; 2009 Aug; 23(6):569-77. PubMed ID: 19585212
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.
Sung YM; Lee KS; Kim BT; Choi JY; Shim YM; Yi CA
J Nucl Med; 2006 Oct; 47(10):1628-34. PubMed ID: 17015898
[TBL] [Abstract][Full Text] [Related]
39. Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor.
Moon SH; Kim HS; Cho YS; Sun JM; Ahn JS; Park K; Kim BT; Ahn MJ; Lee KH
Lung Cancer; 2016 Oct; 100():24-29. PubMed ID: 27597277
[TBL] [Abstract][Full Text] [Related]
40. A novel predictive model for distinguishing mediastinal lymphomas from thymic epithelial tumours.
Wang S; Lin M; Yang X; Lin Z; Wang S; Jiang J; Chen G; Ao Y; Gao J; Shi H; Cheng L; Ding J
Eur J Cardiothorac Surg; 2022 Nov; 62(6):. PubMed ID: 36165700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]